BELITE BIO, INC (BLTE)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

154.49 on 9 Oct 2026

0 buys2 sales at will27 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$77.61M

Free cash flow

$37.06M

Return on equity

-10.1%

Return on capital

-8.6%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
1 Oct 2026	Scholl Hendrik Peter Chief Medical Officer	Sold on a plan	$82.66K	3.3%
8 Sep 2026	Lin Yu-Hsin Chief Executive Officer	Sold on a plan	$5.11M	27.0%
8 Sep 2026	Chuang Hao-Yuan Chief Financial Officer	Sold on a plan	$3.53M	40.8%
4 Sep 2026	Lin Yu-Hsin Chief Executive Officer	Sold on a plan	$13.97M	43.6%
4 Sep 2026	Chuang Hao-Yuan Chief Financial Officer	Sold on a plan	$9.28M	52.9%
12 Aug 2026	Chuang Hao-Yuan Chief Financial Officer	Sold on a plan	$66.19K	0.4%

29out of 100

Profitability 0

Financial strength 70

Growth n/a

Insiders 20

Strongest on financial strength (70), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$40.63M

29 sales

Planned sales

93%

under a 10b5-1 plan